Also known as CTTQ, Sino Biopharm.
- Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)RecruitingNCT07543796Phase 2
Sponsor listed in the registry: Beijing Tide Pharmaceutical Co., Ltd · Beijing Tide Pharmaceutical Co., Ltd — acquired company within the Sino Biopharmaceutical Limited group
- Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor ResponseNot yet recruitingNCT07797231Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part SarcomaRecruitingNCT07548177Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid TumorsEnrolling by invitationNCT07847905Phase 1/2
Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group
- A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy VolunteersRecruitingNCT07909837Phase 1
Sponsor listed in the registry: Nanjing Chia-tai Tianqing Pharmaceutical
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingNCT07043725Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer SubjectsRecruitingNCT07697443Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingNCT05934331Phase 2
Sponsor listed in the registry: LaNova Medicines Zhejiang Co., Ltd. · LaNova Medicines Zhejiang Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)Not yet recruitingNCT07878091Phase 2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle InterventionRecruitingNCT07798284Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has SpreadNot yet recruitingNCT07844187Phase 1/2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseRecruitingNCT07464587Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®RecruitingNCT07663526Phase 4
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.RecruitingNCT07653685Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid TumorsRecruitingNCT07730190Phase 1
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal CancerRecruitingNCT07367516Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced CancersRecruitingNCT07260708Phase 1
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07564505Phase 4
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisRecruitingNCT07724366Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionRecruitingNCT07367529Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative BacteriaRecruitingNCT07512596Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic ArthritisRecruitingNCT07406035Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.Not yet recruitingNCT07794111Phase 1
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingNCT06682780Phase 1/2
Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/ObesityRecruitingNCT07747857Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host DiseaseRecruitingNCT06300320Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- TQC2731 Clinical Trial for the Treatment of Severe Asthma With InjectionRecruitingNCT06829784Phase 3
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant TumorsRecruitingNCT06943677Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Not yet recruitingNCT07753369Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid TumorsNot yet recruitingNCT07738679Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid TumorsRecruitingNCT07669415Phase 2
Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Study of TQB3107 Tablets in Patients With Malignant TumorsRecruitingNCT06413953Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque PsoriasisRecruitingNCT07663331Phase 4
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk MyelofibrosisRecruitingNCT07551427Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid TumorsNot yet recruitingNCT07694765Phase 1/2
Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus ErythematosusRecruitingNCT07509892Phase 2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Phase 3
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant TumorsRecruitingNCT07338838Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid TumorsRecruitingNCT07512583Phase 1/2
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerRecruitingNCT07047365Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)RecruitingNCT07165951Phase 3
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform NeurofibromasRecruitingNCT07407803Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Treatment of Recurrent/Metastatic Head and Neck CancerNot yet recruitingNCT07601204Phase 1/2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseRecruitingNCT06754891Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction AdenocarcinomaRecruitingNCT07362186Phase 3
Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Phase 3
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsRecruitingNCT07266116Phase 1/2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver FunctionNot yet recruitingNCT07538973Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant TumorsRecruitingNCT07482592Phase 1
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque PsoriasisNot yet recruitingNCT07529925Phase 4
Sponsor listed in the registry: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group